Executive Summary
The PARTNER 3 five-year annular-size analysis lands the cleanest blow yet against the durability skeptics: TAVR with SAPIEN 3 matched SAVR for death, stroke, and rehospitalization in both small (≤430 mm²) and large annuli at 5.2 years median follow-up, with bioprosthetic valve failure rates low and equivalent across strata. That neutralizes one of the last surgical rebuttal cards — that small-annulus women get short-changed by TAVR hemodynamics — and tightens the case for ESC 2025's ≥70-year TAVI-preferred stance, though ACC/AHA's <65 SAVR floor holds on durability grounds beyond 5 years. The STS/ACC TVT Registry exposes chaos in valve-in-valve antithrombotic practice: single-antiplatelet, dual-antiplatelet, and OAC regimens ranging from 0% to 100% across sites, with no outcome differences at 1 year across 18,414 patients.
- PARTNER 3 at 5 years: small-annulus TAVR primary endpoint 21.2% vs SAVR 31.0% (OR 0.60, 95% CI 0.35–1.02), no interaction by annular size (JACC Interventions).
- ViV TAVR antithrombotic practice: SAPT use overtook DAPT as the dominant strategy by 2024, with no mortality, stroke, or bleeding differences across regimens (STS/ACC TVT Registry).
- Preoperative gait speed predicted mid-term mortality after mitral TEER (HR 0.81 per 0.1 m/s, AUC 0.749 at 1 year), with 0.8 m/s emerging as a stratification threshold (Diseases).
- Circulation proposed MACE-Cog, a composite cognitive-outcome framework built to capture the post-TAVI and post-CABG cognitive decline that current trials systematically underreport (Circulation).
- Nationwide TAVR antibiotic prophylaxis practice varies without evidence-based standardization (JACC Interventions).
Watch the forthcoming REVERSE-TAVR trial on GLP-1 receptor agonists as perioperative cardioprotective agents in TAVR — the first prospective test of whether a metabolic drug can move cardiac procedural outcomes.
Aortic Valve (TAVR/TAVI)
Small annuli are no longer a TAVR liability at five years. The PARTNER 3 post hoc analysis stratified 925 low-risk patients by CT-derived annular area and found the composite of death, stroke, or rehospitalization at 5.2 years was 21.2% for TAVR vs 31.0% for SAVR in small annuli (OR 0.60, 95% CI 0.35–1.02) and 23.5% vs 25.5% in large annuli, with no interaction (P=0.22) and no signal on bioprosthetic valve failure. Health status was equivalent across strata. [NOTABLE] The finding directly undercuts the surgical argument that small-annulus women — historically underserved by supra-annular TAVR designs — should default to SAVR with root enlargement. This is a post hoc subanalysis of a low-risk cohort with median follow-up just past 5 years; ACC/AHA 2020 still favors SAVR for patients <65, and ESC 2025's SAVR-preferred zone below age 70 rests explicitly on incomplete durability data beyond 10 years. Concurrent editorial commentary in JACC Interventions calls for reconsidering how balloon-expandable hemodynamic parameters are interpreted, and a novel commissural alignment technique was reported — both directly relevant to the lifetime management planning ESC 2025 foregrounded at the index procedure. A separate single-center series reported balloon-expandable TAVI outcomes in large annuli. The nationwide antibiotic prophylaxis variation study makes an adjacent point: TAVR is standardizing on outcomes but not on process.
Mitral Valve (MitraClip, PASCAL, TMVR)
Gait speed, not STS score, may be the more honest prognostic marker before mitral TEER. In a single-center retrospective cohort of 97 patients (mean age 79, 57% male) who survived the first week post-TEER, each 0.1 m/s increase in preoperative gait speed was associated with a 19% lower mortality risk (HR 0.81, 95% CI 0.68–0.97, P=0.02) after adjustment for STS score and handgrip strength. Time-dependent AUCs were 0.749 at 1 year and 0.710 at 2 years, with a 0.8 m/s threshold separating survival curves (log-rank P<0.01). The caveats are real: N=97, single center, retrospective, no external validation of the cutoff. The direction of travel is consistent with the broader frailty literature and with why ESC 2025 elevated M-TEER to Class I for ventricular secondary MR meeting COAPT criteria while still emphasizing patient selection. For primary MR with durable repair prospects, MV repair remains Class I in both ACC/AHA 2020 and ESC 2025; TEER stays Class IIa for high-risk anatomy-suitable patients only. Frailty screening pushes patients away from surgery and toward TEER, but the same frailty that makes TEER attractive also predicts poor TEER outcomes — a paradox this study crystallizes without resolving.
Surgical vs. Transcatheter Comparisons
PARTNER 3's annular-size subanalysis is today's head-to-head, and it is meaningful. Five-year TAVR outcomes matched SAVR across annular strata in the low-risk cohort where the surgical prior was strongest on hemodynamic grounds. The 5-year rate of bioprosthetic valve failure was low in both arms — that number will determine whether ACC/AHA 2020 shifts its <65 SAVR floor at the next update. What the sources do not provide: any 10-year TAVR durability signal, which is where Badhwar, Mehaffey, and Chikwe have consistently held the line for surgical preference. ESC 2025's Class I TAVI recommendation at age ≥70 with tricuspid anatomy and transfemoral access is now supported by five-year data across annular geometries; the ACC/AHA framework, which places 65–80 in shared decision-making, is now the more conservative of the two by a measurable margin.
Device & Technology
A novel implantation technique for commissural alignment in transcatheter aortic valves was reported in JACC Interventions — an incremental but consequential advance for lifetime management, where poor commissural alignment complicates future valve-in-valve procedures and coronary reaccess. ESC 2025 explicitly flagged commissural alignment as part of index-procedure planning when life expectancy exceeds assumed valve durability. An accompanying editorial argues balloon-expandable hemodynamic parameters need reinterpretation in light of contemporary imaging and lifetime-management demands.
Clinical Trial Updates
The STS/ACC TVT Registry ViV TAVR analysis (N=18,414, 2015–2024) documents a decade of practice drift without evidence: DAPT dropped from majority to minority as SAPT took over, site-level variation ranged from 0% to 100% for each regimen, and adjusted 1-year mortality, stroke, and bleeding were equivalent across SAPT, DAPT, and OAC-based strategies. The accompanying editorial calls for a randomized trial. The registry design cannot adjudicate residual confounding, but a null result across 18,414 patients constrains any true effect to small. The Circulation MACE-Cog framework is a methodological shift: current cardiovascular trials underreport cognitive outcomes, and post-TAVI cognitive decline is a known but under-measured signal. If MACE-Cog is adopted as a trial endpoint, TAVR vs SAVR comparisons in younger patients may look different than they do on hard cardiovascular composites alone — a material consideration given the ESC 2025 push toward TAVI at age 70. The REVERSE-TAVR trial on GLP-1 RAs as perioperative cardioprotection is upcoming.
Preprint Highlights
Today's bioRxiv preprint on candidate ribozyme-like circular RNAs from Finnish tundra soil is outside the valve remit but flagged for completeness. No structural heart relevance.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $83.04, -0.93% on the day, +1.44% over six months
- Market cap $47.8B, trailing P/E 49.14, forward P/E 24.61, beta 0.85, 52-week range $72.30–$96.29
- Analyst target $100.48 (range $84–$110, 25 analysts), consensus buy
- Next earnings 2026-07-23, EPS est $0.74, revenue est $1.68B
Edwards drifted while peers rallied. The PARTNER 3 annular-size data — SAPIEN 3 matching SAVR in small annuli at 5 years — is a durable tailwind for the balloon-expandable franchise and for the small-annulus female patient segment where Medtronic's supra-annular Evolut has historically claimed hemodynamic superiority. The market has not yet priced this.
Medtronic (MDT)
- Close: $84.22, +2.69% on the day, -15.00% over six months
- Market cap $107.8B, trailing P/E 22.34, forward P/E 13.15, beta 0.58, 52-week range $73.31–$106.33
- Analyst target $97.84 (range $78–$121, 25 analysts), consensus buy
- Next earnings 2026-09-01, EPS est $1.39, revenue est $9.55B
A 2.7% bounce off a six-month drawdown of 15%. The PARTNER 3 finding is a modest headwind for Evolut's small-annulus positioning, but Medtronic's structural heart franchise diversification limits single-trial exposure. Forward P/E of 13 remains the cheapest valuation in the group.
Abbott (ABT)
- Close: $104.49, +3.71% on the day, -0.15% over six months
- Market cap $182.0B, trailing P/E 33.38, forward P/E 17.23, beta 0.61, 52-week range $81.97–$137.49
- Analyst target $119.12 (range $103–$135, 24 analysts), consensus buy
- Next earnings 2026-10-14, EPS est $1.42, revenue est $12.99B
The TEER gait-speed data reinforces frailty as a MitraClip patient-selection axis — a modest positive for procedural volume as referral pathways tighten around COAPT-like criteria. TriClip momentum continues to reflect ESC 2025's Class IIa transcatheter TR endorsement.
Boston Scientific (BSX)
- Close: $45.51, +2.85% on the day, -51.48% over six months
- Market cap $67.6B, trailing P/E 19.04, forward P/E 12.26, beta 0.58, 52-week range $42.20–$109.50
- Analyst target $72.43 (range $55–$106, 28 analysts), consensus strong buy
- Next earnings 2026-07-29, EPS est $0.83, revenue est $5.37B
The six-month decline is severe and unexplained by today's clinical news. Earnings 2026-07-29 will be the tell. Analyst consensus holds strong buy at a $72 target, implying 59% upside from the current print — a gap that reflects either mispricing or a thesis break that consensus has not caught up to.
Anteris Technologies (AVR.AX)
- Close: A$11.50, unchanged on the day, +24.19% over six months
- Market cap A$1.1B, forward P/E -5.27, beta 0.73, 52-week range A$4.86–$15.47
- Analyst target A$13.00 (single analyst)
DurAVR development-stage story. Six-month appreciation of 24% reflects clinical milestone optimism rather than fundamentals.
Market outlook: The PARTNER 3 annular-size data is the most consequential structural heart clinical read of the quarter for Edwards. It closes a durability-adjacent gap in the low-risk case at 5 years and puts the ACC/AHA <65 SAVR floor under fresh pressure ahead of the next guideline update. For the sector broadly, the ViV TAVR antithrombotic registry marks where the field remains evidence-free — and where a randomized trial could reshape peri-procedural care economics.
Watch the 10-year PARTNER 3 and Evolut Low Risk follow-ups. Five-year data is now settled across annular geometries, cohorts, and manufacturers. The next inflection is durability past a decade — the only remaining surgical rebuttal ACC/AHA can hold in its next update.